Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

518
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

596
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
596

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same author

Corrigendum to 'Role of CD40 in prion disease and the immune response to recombinant PrP' [Journal of Neuroimmunology 257 (2013) 21-27/475655].

Journal of neuroimmunology·2026
Same author

Interconnected influences of diet, gut microbiome, and metabolome on cognition across three metabolomics platforms.

Research square·2026
Same author

Short T1 Fraction as a Marker of Myelin Content: Evidence from Postmortem MRI and Histology.

bioRxiv : the preprint server for biology·2026
Same author

Amygdala microstructural changes in subjective cognitive decline: A diffusion kurtosis and neurite orientation dispersion and density imaging study.

Journal of Alzheimer's disease : JAD·2026
Same author

Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration.

Acta neuropathologica·2026
Same journal

Preface.

Handbook of clinical neurology·2026
Same journal

Foreword.

Handbook of clinical neurology·2026
Same journal

Fundus autofluorescence imaging.

Handbook of clinical neurology·2026
Same journal

The electroretinogram as a means to study the physiology of the retina.

Handbook of clinical neurology·2026
Same journal

Adaptive optics scanning light ophthalmoscopy.

Handbook of clinical neurology·2026
Same journal

Modeling the human retina in a dish: Advances and future directions.

Handbook of clinical neurology·2026
See all related articles

Related Experiment Video

Updated: Jul 18, 2025

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

12.0K

Gait dysfunction in Alzheimer disease.

Thomas Wisniewski1, Arjun V Masurkar2

  • 1Department of Neurology, NYU School of Medicine, New York, NY, United States; Department of Pathology, NYU School of Medicine, New York, NY, United States; Department of Psychiatry, NYU School of Medicine, New York, NY, United States; Division of Cognitive Neurology, Center for Cognitive Neurology, NYU School of Medicine, New York, NY, United States.

Handbook of Clinical Neurology
|August 24, 2023
PubMed
Summary
This summary is machine-generated.

Gait dysfunction is an early sign of Alzheimer's disease (AD). Assessing walking patterns can help detect AD early and predict cognitive decline.

Keywords:
Alzheimer diseaseAmyloidBiomarkersClinical syndromesGaitMotor disorders

More Related Videos

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

2.8K
Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion
08:19

Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion

Published on: January 15, 2016

8.9K

Related Experiment Videos

Last Updated: Jul 18, 2025

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

12.0K
Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

2.8K
Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion
08:19

Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion

Published on: January 15, 2016

8.9K

Area of Science:

  • Neurology
  • Geriatrics
  • Movement Science

Background:

  • Alzheimer's disease (AD) is the leading cause of dementia, with rising prevalence.
  • AD is increasingly recognized to involve motor symptoms, notably gait dysfunction.
  • Early detection and disease-modifying strategies are crucial for managing AD.

Conclusions:

  • Gait assessment offers a valuable, non-invasive method for early AD detection.
  • Quantitative gait analysis can identify subtle motor deficits indicative of AD.
  • Integrating gait assessment into clinical practice can improve early identification of at-risk individuals.